Paradigm BioCapital Advisors LP Acquires 6.1% Stake in Maze Therapeutics, Inc.

Paradigm BioCapital Advisors LP, along with its affiliates Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., filed a Schedule 13G on April 1, 2026, disclosing a new 6.1% stake in Maze Therapeutics, Inc. (MAZE). The reporting group collectively beneficially owns 3,051,087 shares of common stock. Specifically, Paradigm BioCapital International Fund Ltd. directly holds 2,688,520 of these shares (5.4%), while the remaining shares are held through separately managed accounts. Senai Asefaw, as the managing member of the Adviser GP, may be deemed to share beneficial ownership of the total position. This filing was triggered by reaching the ownership threshold on March 25, 2026. The filing is passive in nature, as indicated by the Rule 13d-1(c) designation and the certification that the shares were not acquired for the purpose of influencing control of the issuer. The percentages are based on 49,708,658 shares outstanding as of March 20, 2026.